Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$14.16 USD
+0.44 (3.21%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $14.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TAK 14.16 +0.44(3.21%)
Will TAK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
Will Strong Asceniv Sales Drive ADMA Biologics Further?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
Other News for TAK
Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript
TAK Crosses Below Key Moving Average Level
Takeda (TAK) Reaffirms FY25 Financial Projections
Takeda (TAK) Reports Decline in Q1 Revenue Amid Potential Pipeline Growth
Takeda reports Q1 core EPS 151 yen vs. 176 yen last year